Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 57.85M P/E - EPS this Y 41.60% Ern Qtrly Grth -
Income -45.61M Forward P/E -1.39 EPS next Y 11.10% 50D Avg Chg 3.00%
Sales 21.48M PEG -0.11 EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book 0.82 EPS next 5Y 17.00% 52W High Chg -50.00%
Recommedations 2.00 Quick Ratio 2.66 Shares Outstanding 6.35M 52W Low Chg 44.00%
Insider Own 31.62% ROA -34.72% Shares Float 3.84M Beta 0.65
Inst Own 18.55% ROE -101.78% Shares Shorted/Prior 23.10K/10.28K Price 1.11
Gross Margin -132.62% Profit Margin -212.33% Avg. Volume 104,867 Target Price 35.50
Oper. Margin -143.01% Earnings Date Nov 6 Volume 75,741 Change 1.83%
About Assembly Biosciences, Inc.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Assembly Biosciences, Inc. News
12/19/24 Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
11/13/24 Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates
11/07/24 Assembly Biosciences: Q3 Earnings Snapshot
11/07/24 Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
10/02/24 Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
09/23/24 Assembly Biosciences' Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED)
09/23/24 Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
09/16/24 Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?
08/30/24 Is Sensus Healthcare (SRTS) Stock Outpacing Its Medical Peers This Year?
08/29/24 Individual investors in Assembly Biosciences, Inc. (NASDAQ:ASMB) are its biggest bettors, and their bets paid off as stock gained 14% last week
08/08/24 Assembly Biosciences: Q2 Earnings Snapshot
08/08/24 Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
07/19/24 Investors in Assembly Biosciences (NASDAQ:ASMB) have unfortunately lost 90% over the last five years
07/15/24 Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
06/18/24 Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
06/17/24 Assembly Biosciences Announces $12.6 Million in Equity Financings
06/10/24 Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
06/05/24 Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
07:00 AM Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
05/16/24 Are Medical Stocks Lagging Entera Bio (ENTX) This Year?
ASMB Chatroom

User Image Stronx Posted - 1 day ago

$ASMB why would anybody sell this when gild bought above 20$

User Image wonapenny Posted - 1 day ago

$ASMB uuugghhh this stock 😵‍💫😵‍💫😵‍💫😵‍💫😵‍💫 just come out with news that one of your drugs actually works already. Their Dec 2024 presentation still says 4334 data is coming out by end of year. they'll drop it at 11:59 pm 12/31. 🙄🙄🙄🙄

User Image BioMan122 Posted - 1 day ago

$ASMB just follow the smart money…

User Image BioMan122 Posted - 1 day ago

$ASMB do you understand??? $GILD payed over $21 for this according to YESTERDAY news.

User Image BioMan122 Posted - 1 day ago

$ASMB gilead payed over $21 for this!!! means they are convinced stockprice to be higher soon!!!

User Image HanSolo123 Posted - 1 day ago

$ASMB I wonder, why the trading volume after news was so low. I mean $GILD bought at a premium of approx. $21. Share price is literally still lower than it was last week. High chance we might run like $ALGS, but we need to spread the word and get more attention... https://endpts.com/gilead-deepens-its-stake-in-assembly-biosciences-ngm-licenses-out-mash-drug/

User Image wonapenny Posted - 2 days ago

$ASMB they keep de-emphasizing 4334 and playing up the HPIs and HVD candidate more. The press release doesn't even mention 4334 1b results due any day now.

User Image macrossluvsrobotech Posted - 2 days ago

$GILD now owns 30% of $ASMB

User Image macrossluvsrobotech Posted - 2 days ago

$GILD + $ASMB A New Catalyst arrives on the scene,amongst many: "Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus (HDV) and hepatitis B virus (HBV). Assembly Bio expects to release data from multiple ongoing clinical studies in the coming year, including the interim Phase 1b proof-of-concept data readout for ABI-5366 projected for the first half of 2025." https://www.manilatimes.net/2024/12/19/tmt-newswire/globenewswire/assembly-biosciences-announces-301-million-equity-investment-and-accelerated-funding-from-gilead-to-advance-clinical-development-programs/2025003

User Image Zonata Posted - 2 days ago

$ASMB "With the new equity investment, Gilead increases its equity ownership of Assembly Bio to 29.9%." IMO, this is a very good news. ASMB will be trading above 30$ next year if all goes well.

User Image BioMan122 Posted - 2 days ago

$ASMB at least thats something! there will be one day not too far it will be too late to get in at those cheap prices…some will surely deeply regret!

User Image wonapenny Posted - 2 days ago

$ASMB great news!! Disappointing that it isn't breaking share price out of the usual range, though. Let's hope 4334 comes through.

User Image Stronx Posted - 2 days ago

$ASMB December 19, 2024, Gilead elected to purchase an additional 940,499 shares (the “Additional Shares”) of the Company’s common stock at a purchase price of $21.37 per share

User Image RallyRaider Posted - 2 days ago

$ASMB Herr Schornstein hat sicher eine gute Zeit. Seine Follower machen sich noch immer das Selbstmitleid zum Hobby und folgen diesem dämlichen Newsletter statt den EDGAR-Filings von Herrn Schornstein.

User Image Norissa Posted - 2 days ago

$ASMB very clear purchase prices. sd positions itself.

User Image Norissa Posted - 2 days ago

$ASMB MEGA NEWS!!! Cheap pieces still available! https://investor.assemblybio.com/node/13561/html https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-announces-301-million-equity-investment-and

User Image Norissa Posted - 2 days ago

$ASMB new investors coming? youtu.be/THIu7FQAXBI?si=pspSjrLZFv6VlbdA&t=894

User Image Norissa Posted - 2 days ago

$ASMB What's going on here? Now 4 clinical assets launched. It's very hot https://clinicaltrials.gov/search?spons=Assembly

User Image Stronx Posted - 3 days ago

$ASMB ridiculous!

User Image BioMan122 Posted - 3 days ago

$ASMB they are going to ruin holidays for us

User Image phu0000 Posted - 3 days ago

$ASMB a lot more is brewing in the innercircle of that company.

User Image SearchFor911 Posted - 4 days ago

$ASMB news incoming?!?!

User Image BioMan122 Posted - 4 days ago

$ASMB this doesnt look like good data are going to be released…

User Image BioMan122 Posted - 4 days ago

$ASMB we‘re doomed

User Image BioMan122 Posted - 4 days ago

$ASMB jason, be a good boy this year…

User Image BioMan122 Posted - 4 days ago

$ASMB dont play games with us, jason!

User Image BioMan122 Posted - 4 days ago

$ASMB it seems like they are going to ruin it

User Image Mmoney2424 Posted - 5 days ago

$ASMB is this it. NNOX

User Image BioMan122 Posted - 5 days ago

$ASMB DO NOT RUIN IT!!!

User Image BioMan122 Posted - 5 days ago

$ASMB please do not ruin our christmas!

Analyst Ratings
HC Wainwright & Co. Neutral Jun 20, 24
HC Wainwright & Co. Neutral Jun 13, 24
HC Wainwright & Co. Neutral Apr 1, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Schornstein Alexander 10% Owner 10% Owner Jan 17 Buy 0.79 645,080 509,613 8,209,372 01/19/24
Okazaki Jason A CEO and President CEO and President Aug 02 Sell 1.0879 11,827 12,867 164,786 08/03/23
McHutchison John G Director Director May 22 Sell 1.04 25,972 27,011 169,160 05/24/23
Bjorkquist Jeanette M Principal Accounting.. Principal Accounting Officer May 22 Sell 1.04 274 285 27,532 05/24/23
Delaney William E IV Chief Scientific Off.. Chief Scientific Officer May 22 Sell 1.04 6,561 6,823 116,437 05/24/23
Okazaki Jason A CEO and President CEO and President May 22 Sell 1.04 6,561 6,823 126,613 05/24/23
McHutchison John G Director Director Mar 30 Sell 0.8232 14,883 12,252 177,632 03/31/23
Bjorkquist Jeanette M Principal Accounting.. Principal Accounting Officer Feb 16 Sell 0.82 774 635 23,806 03/31/23
Delaney William E IV Chief Scientific Off.. Chief Scientific Officer Mar 29 Sell 0.8232 3,421 2,816 85,498 03/31/23
McHutchison John G Chief Executive Offi.. Chief Executive Officer Aug 08 Sell 2.1277 12,314 26,200 192,515 08/10/22
Samar Michael P. Chief Financial Offi.. Chief Financial Officer Jul 25 Sell 2.2174 2,020 4,479 77,228 07/26/22
Delaney William E IV Chief Scientific Off.. Chief Scientific Officer May 31 Sell 1.9224 4,164 8,005 76,419 06/02/22
Samar Michael P. Chief Financial Offi.. Chief Financial Officer Mar 29 Sell 2.17 2,285 4,958 76,748 03/31/22
Stamm Luisa M Chief Medical Office.. Chief Medical Officer Mar 29 Sell 2.17 1,038 2,252 40,315 03/31/22
Delaney William E IV Chief Scientific Off.. Chief Scientific Officer Mar 29 Sell 2.17 1,038 2,252 78,083 03/31/22
Okazaki Jason A Chief Operating Offi.. Chief Operating Officer Mar 29 Sell 2.17 1,269 2,754 94,614 03/31/22
McHutchison John G CEO and President CEO and President Mar 29 Sell 2.17 4,614 10,012 204,829 03/31/22
Okazaki Jason A Chief Operating Offi.. Chief Operating Officer Mar 28 Sell 2.2445 4,617 10,363 64,633 03/29/22